Improving In Vivo Brain Delivery of Monoclonal Antibody Using Novel Cyclic Peptides.

Pharmaceutics · 2019 · PMC6920923 · PMID 31683745

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)

Cyclic ADTHAV showed a trend of higher activity in delivering IgG mAb compared to linear ADTHAV ( p = 0.07), whereas there was no significant difference between cyclic ADTHAV and ADTC5 ( p = 0.20).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.